지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2021.10
- 수록면
- 386 - 397 (12page)
- DOI
- 10.5217/ir.2020.00080
이용수
초록· 키워드
오류제보하기
Background/Aims: We aimed to evaluate the efficacy and safety of ustekinumab (UST) in the East-Asian population with moderate to severely active ulcerative colitis (UC).Methods: This sub-analysis was conducted on data from East-Asian patients included in the UNIFI program (NCT02407236). UNIFI consisted of two double-blind, placebo-controlled trials: an 8-week induction study and a 44-week randomized withdrawal maintenance study.Results: Of 133 East-Asian patients (Japanese: 107, Korean: 26) who underwent randomization, 131 completed induction study and 111 entered maintenance study. In the maintenance study, 78 patients were randomized. Patients who received UST 130 mg and UST 6 mg/kg showed numerically higher clinical remission at week 8 in the induction study (5/44 [11.4%] and 5/45 [11.1%], respectively) compared with those who received placebo (0/44, 0%). The proportion of patients achieved clinical remission at week 44 was numerically higher in the UST 90 mg q12w group (10/21, 47.6%), but similar in the UST 90 mg q8w group (5/26, 19.2%) compared to placebo (7/31, 22.6%). Serious adverse events were reported in 1 patient in UST 130 mg group, but no patient in UST 6 mg/kg group through week 8 in the induction study, and 1 patient in UST 90 mg q12w group and 5 patients in the UST 90 mg q8w group in the maintenance study. No deaths were reported in East-Asian patients throughout the study.Conclusions: UST induction and maintenance treatments were effective in East-Asian patients with moderate to severe UC; the efficacy and safety profiles were consistent with the overall population.
목차
등록된 정보가 없습니다.
참고문헌 (30)
참고문헌 신청
Stenson WF / 2000 / Cecil textbook of medicine / WB Saunders Co. :722~729
Ng SC / 2016 / Emerging trends of inflammatory bowel disease in Asia / Gastroenterol Hepatol(N Y) 12:193~196
Murakami Y / 2019 / Estimated prevalence of ulcerative colitis and Crohn’s disease in Japan in 2014 : an analysis of a nationwide survey / J Gastroenterol 54:1070~1077
World Gastroenterology Organisation / 2017 / WGO handbook on inflammatory bowel disease (IBD): navigating evolving therapies in an evolving disease / WGO
Wee Khoon Ng / 2016 / Changing epidemiological trends of inflammatory bowel disease in Asia / Intestinal research 14(2):111~119
Ng SC / 2016 / Emerging trends of inflammatory bowel disease in Asia / Gastroenterol Hepatol(N Y) 12:193~196
Murakami Y / 2019 / Estimated prevalence of ulcerative colitis and Crohn’s disease in Japan in 2014 : an analysis of a nationwide survey / J Gastroenterol 54:1070~1077
World Gastroenterology Organisation / 2017 / WGO handbook on inflammatory bowel disease (IBD): navigating evolving therapies in an evolving disease / WGO
Wee Khoon Ng / 2016 / Changing epidemiological trends of inflammatory bowel disease in Asia / Intestinal research 14(2):111~119
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Real-world effectiveness and safety of ustekinumab induction therapy for Korean patients with Crohn’s disease: a KASID prospective multicenter study
Intestinal research
2023 .01
-
Ulcerative Colitis and Patient’s Quality of Life, Especially in Early Stage
Gut and Liver
2022 .05
-
Endoscopic Mucosal Healing as a Treatment Target in Ulcerative Colitis: Does It Have the Same Role in Asian Patients?
Gut and Liver
2021 .11
-
The Evolving Concept of Dual Antiplatelet Therapy after Percutaneous Coronary Intervention: Focus on Unique Feature of East Asian and “Asian Paradox”
Korean Circulation Journal
2018 .01
-
Ustekinumab for anti-tumor necrosis factor refractory pediatric ulcerative colitis: a promising approach towards endoscopic healing
Intestinal research
2024 .07
-
Factors related to Quality of Life of Patients with Ulcerative Colitis
성인간호학회 학술대회
2015 .04
-
Efficacy and safety of filgotinib as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a post-hoc analysis of the phase 2b/3 SELECTION trial
Intestinal research
2023 .01
-
Efficacy and safety of ustekinumab in Japanese patients with moderately to severely active Crohn’s disease: a subpopulation analysis of phase 3 induction and maintenance studies
Intestinal research
2017 .01
-
Safety and effectiveness of adalimumab in the treatment of ulcerative colitis: results from a large-scale, prospective, multicenter, observational study
Intestinal research
2021 .10
-
Clinical outcomes and predictors of response for adalimumab in patients with moderately to severely active ulcerative colitis: a KASID prospective multicenter cohort study
Intestinal research
2022 .07
-
Correlation of fecal calprotectin and patient-reported outcome measures in patients with ulcerative colitis
Intestinal research
2022 .04
-
Efficacy and Safety of Adalimumab in Moderately to Severely Active Cases of Ulcerative Colitis: A Meta-Analysis of Published Placebo-Controlled Trials
Gut and Liver
2016 .01
-
Understanding the Role of Adalimumab in the Treatment of Moderately to Severely Active Ulcerative Colitis
Gut and Liver
2016 .01
-
Efficacy and safety of abrilumab, an α4β7 integrin inhibitor, in Japanese patients with moderate-to-severe ulcerative colitis: a phase II study
Intestinal research
2019 .01
-
포커스 그룹 인터뷰를 이용한 환자안전전담자의 환자 및 보호자 대상 환자 안전 교육 경험 분석
한국의료질향상학회지
2019 .01
-
의원급 의료기관 환자의 환자경험과 환자안전인식의 관계에서 환자안전지식의 조절효과
성인간호학회지
2021 .08
-
Role of Smoking as a Risk Factor in East Asian Patients with Crohn's Disease
Gut and Liver
2017 .01
-
의과대학생을 위한 환자안전 교육의 국제적 동향 및 국내 현황
의학교육논단
2019 .01
-
Real-world data for golimumab treatment in patients with ulcerative colitis in Japan: interim analysis in post-marketing surveillance
Intestinal research
2022 .07
이 논문의 저자 정보
최근 본 자료
댓글(0)
0